EW
Edwards Lifesciences Corp
NYSE · Healthcare · Medical - Devices · US
$87.22
+0.72%Oct 8, 2026, 23:59 UTC
The European Commission selected products from Edwards Lifesciences Corp and HighLife SAS as the first medical devices to undergo joint clinical assessment.
Source:Oct 7, 2026, 10:00 UTC
Edwards Lifesciences Corp plans to announce its operating results for the quarter ended September 30, 2026, after market close on November 4, 2026, and host a conference call that day at 5:00 p.m. ET.
Source:Oct 5, 2026, 10:00 UTC
Edwards Lifesciences announced it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Nov. 2, 2026.
Source:Oct 1, 2026, 20:26 UTC
The U.S. Food and Drug Administration approved Edwards Lifesciences' AUTUS Size-Adjustable Valve, the first surgical pulmonary valve designed for pediatric patients with congenital heart disease.
Source:Sep 23, 2026, 08:15 UTC
China's National Medical Products Administration approved three additional valve-in-valve indications for Edwards Lifesciences' SAPIEN 3 transcatheter heart valve system, making it the first transcatheter heart valve in China with three valve-in-valve indications.
Source:Sep 11, 2026, 23:45 UTC
Daniel J. Lippis, CVP, TAVR at Edwards Lifesciences Corp, sold 619 shares of the company's common stock for $54,168 on September 11, 2026, and concurrently acquired 619 shares via employee stock option exercise at $72.68 per share.
Source:Sep 10, 2026, 21:49 UTC
The Centers for Medicare & Medicaid Services released a national coverage determination for transcatheter aortic valve replacement (TAVR), prompting a statement from Edwards Lifesciences.
Source:Aug 28, 2026, 20:20 UTC
Donald E. Bobo, Jr. retired as Corporate Vice President of Strategy and Corporate Development at Edwards Lifesciences Corp.
Aug 23, 2026, 08:30 UTC
EP Wealth Advisors LLC acquired a new position in Edwards Lifesciences Corporation by purchasing 37,702 shares valued at approximately $3,410,000, as disclosed in a recent SEC filing.
Source:Aug 22, 2026, 07:57 UTC
B. Metzler seel. Sohn & Co. AG acquired a new position of 41,753 shares in Edwards Lifesciences Corporation during the second quarter, valued at approximately $3,777,000.
Source:Aug 22, 2026, 07:11 UTC
Allworth Financial LP acquired a new position in Edwards Lifesciences Corporation, buying 16,600 shares valued at approximately $1,502,000 during the second quarter, as disclosed in a 13F filing.
Source:Aug 17, 2026, 08:33 UTC
Baxter Bros Inc. disclosed a new minority stake in Edwards Lifesciences Corporation, purchasing 39,184 shares valued at approximately $3.54 million during the undefined quarter.
Source:Jul 24, 2026, 00:30 UTC
The FTC secured $12 million in penalties from Edwards Lifesciences Corp. and Genesis MedTech Group Limited for failing to make a Hart-Scott-Rodino filing.
Source:Jul 23, 2026, 20:15 UTC
Edwards Lifesciences reported financial results for the second quarter ended June 30, 2026, with sales of $1.74 billion and EPS of $0.42.
Jul 16, 2026, 04:29 UTC
Jenscare Scientific's LuX-Valve Plus system completed the first patient implantations in the FDA-approved pivotal clinical trial in the United States.
Source: